Korean J Obes.
2005 Mar;14(1):29-38.
An Activation of Peroxisome Proliferator-Activated Receptor delta Attenuate Alcoholic Liver Disease and Nonalcoholic Fatty Liver Disease in Rats
- Affiliations
-
- 1Department of Family Medicine, College of Medicine, Korea University, Seoul, Korea. ksmpdh@paran.com
- 2Biomedical Research Center, Korea Institute of Science and Technology, Seoul. Korea.
Abstract
-
BACKGROUND: Author used the rat model of alcoholic and nonalcoholic liver disease in which feeding dietary with ethanol and high fat result in the development of fatty liver, necrosis, and inflammation. Author used PPAR-delta agonist in study group. Author investigated that pharmacological PPAR-delta agonist can treat not only the pathological manifestations of alcohol or high fat induced liver injury but also alcohol or high fat induced biochemical and histological inflammatory changes in liver.
METHODS
Rats were divided into five groups by diet and treatment; a liquid control diet group, a liquid high-fat diet group; a liquid high-fat diet with PPAR-delta agonist L-165041 treatment group; a liquid ethanol diet group; and liquid ethanol diet with PPAR-delta agonist L-165041 treatment group. Here we investigated the role of PPAR-delta agonist in alcoholic and nonalcoholic liver injury, and showed the biochemistry measurements and pathologic finding of treatment of alcoholic fatty liver disease and nonalcoholic fatty liver disease with PPAR-delta agonist L165041.
RESULTS
PPAR-delta agonist eliminated high-fat and ethanol feeding-induced liver steatosis and reduced weight gain(P<0.05). PPAR-delta agonist treatment induced significantly decreases in alanine aminotransferase(P<0.05), total cholesterol(P<0.05), and insulin(P<0.05) and increases in high density lipoprotein cholesterol(P<0.05) in plasma, in nonalcoholic fatty liver disease. Rats with alcoholic and nonalcoholic fatty liver disease challenged with PPAR-delta agonist treatment had no obvious effects on the levels of plasma adiponectin and TNF-alpha.
CONCLUSION
This study suggests a protective role for PPAR-delta in alcoholic and nonalcoholic fatty liver disease, with possible no involvement of adiponectin.